Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.
about
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryThe current state of adverse event reporting in hemophilia.A new recombinant factor VIII: from genetics to clinical use.Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyPatient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.A public health approach to the prevention of inhibitors in hemophilia.Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.Inhibitors - genetic and environmental factors.Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH.Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.Emerging drugs for the treatment of hemophilia A and B.Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.Health economic models in hemophilia A and utility assumptions from a clinician's perspective.Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward.Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate® : Final report from a prospective study.A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
P2860
Q24188177-8C9FCC13-5B35-4C43-A655-97B81B19AEF4Q30239952-F4FC8F8E-F37F-4AE9-AA8C-2EA641CD8EE2Q30370282-2B02E990-40FC-4563-878A-181AA06CC14CQ30958570-520FD989-2A06-4E45-A3B0-857F08F663E9Q34416394-7B75081E-D4EC-4487-BA34-6BAC896A51E6Q35209354-561CB1DE-5A95-4F09-B36C-EDCBF9D4D367Q35747998-5F8786D1-404D-456E-AA72-7AB1A9D99304Q37381565-F54A3ED8-A405-4747-9891-E53F7B8565BDQ38206856-4F973432-9F75-47AE-BC90-9FB436A581E0Q38224295-00A9FBE5-A045-497F-9DF4-FB75602116A1Q38833988-33D4B3E1-5022-4EFB-81B9-0D264D5E73D9Q38835294-30B49BFD-E27F-43F2-B941-584D635A13CAQ38840145-5FBCE02D-DDE9-467E-9788-B8935501B2C7Q38888065-83E44AC7-26B0-4476-8C01-3C3D00DCF9DCQ38933707-EEF24023-2FB3-48E6-BF06-C5FE5A64B4D4Q38958322-5F8A29ED-BB94-4BAB-A6A4-84247A707B51Q40938357-DFCE14AD-06E8-49D2-914C-7FBCF9E50F28Q45867907-887BD2AA-63ED-4141-A849-F761476E5B9CQ45873084-BF684326-B2D3-4CC8-8A9D-1D4F5B8D55C0Q45875309-F13BE758-005E-479C-A7C8-69C38C3C4BF5Q45875555-59032ED5-E585-4D30-B90B-86EA6825189AQ47556737-DD928D72-AA8A-4114-9876-095FAAC36A99Q52744090-0411A8FA-62D3-4159-B4C9-B742D8268C60
P2860
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Inhibitor development in previ ...... analysis, and meta-regression.
@ast
Inhibitor development in previ ...... analysis, and meta-regression.
@en
Inhibitor development in previ ...... analysis, and meta-regression.
@nl
type
label
Inhibitor development in previ ...... analysis, and meta-regression.
@ast
Inhibitor development in previ ...... analysis, and meta-regression.
@en
Inhibitor development in previ ...... analysis, and meta-regression.
@nl
prefLabel
Inhibitor development in previ ...... analysis, and meta-regression.
@ast
Inhibitor development in previ ...... analysis, and meta-regression.
@en
Inhibitor development in previ ...... analysis, and meta-regression.
@nl
P2093
P2860
P921
P356
P1476
Inhibitor development in previ ...... analysis, and meta-regression.
@en
P2093
P2860
P304
P356
10.1111/JTH.12335
P577
2013-09-01T00:00:00Z